Sunday, October 31, 2010
Saturday, October 30, 2010
Friday, October 29, 2010
Hey Friends! Izzy is in a photo contest. She needs your votes to win. Click on the like button for her! http://ping.fm/UmKjy
Pure Bioscience Announces Distribution Agreement
PURE Bioscience Announces Distribution Agreement for SDC-Based IV-7 Products in Middle East
SAN DIEGO (October 28, 2010) – PURE Bioscience (NASDAQ: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that its marketing partner, Richmont Sciences (Richmont), has established distribution of PURE’s SDC-based IV-7™ products in the Middle East region. Under this arrangement, PURE sells IV-7 products to Richmont for resale into the Middle East, where the IV-7 water treatment and disinfection products have been registered by the United Arab Emirates-Dubai Municipality. Richmont is initially focusing on distribution of IV-7 Water Treatment™.
Michael L. Krall, President and CEO of PURE Bioscience, stated, “Much of the Middle East’s drinking water is produced from desalination plants, and protecting stored drinking water from contamination and microbial growth presents a challenge to government, industry and consumers. We look forward to working with Richmont to provide a range of SDC-based products throughout the region.”
“The water purification and disinfecting technology of IV-7 products is a major scientific advance,” said John Rochon, Chairman of Richmont. “Safe water is a precious gift. Every day, far too many people become sick or even die from drinking or being exposed to contaminated water. This disaster can and must be prevented. We are determined to bring this new, lifesaving water treatment technology to families throughout the world.”
Richmont said that it has reached an agreement with Dubai-based High Scope General Trading LLC (High Scope) for the sale of IV-7 products in the Middle East region. “We are very pleased to join with High Scope in this effort and they will be an outstanding partner with us to bring IV-7 products to government, businesses and consumers,” said Mr. Rochon.
IV-7 Water Treatment contains PURE’s SDC technology, based on a proprietary molecule of ionic silver stabilized in citric acid. When used as directed for drinking water, the product provides safe, tasteless and odorless protection and can substantially reduce the incidence of gastrointestinal illness caused by contaminated water. As few as two ounces of IV-7 Water Treatment can treat 200 gallons of water in just minutes with no harm to the environment and no toxic side effects.
About IV-7 Products
IV-7 Ultimate Germ Defense™ can be used to kill germs on hard surfaces in a wide variety of settings, such as homes, offices, schools, hospitals, medical and dental clinics, restaurants, hotels, animal shelters, public facilities and many more. Unlike traditional alcohol- or bleach-based surface disinfectants, IV-7 Ultimate Germ Defense requires no hazard or warning statements and carries bacterial kill times as quick as 30 seconds, compared with up to 10 minutes for competing products. IV-7 Ultimate Germ Defense provides powerful protection – even against resistant pathogens such as MRSA – and continues to kill bacteria for up to 24 hours after usage; yet, with its EPA Category IV rating, the least-toxic classification, IV-7 Ultimate Germ Defense is also ideal for use in sensitive children’s areas.
IV-7 Ultimate Germ Defense for Food Contact Surfaces™ harnesses the same broad-spectrum disinfecting power as Ultimate Germ Defense combined with registration by the US EPA for food contact surface sanitization while maintaining the EPA Category IV rating. IV-7 Ultimate Germ Defense for Food Contact Surfaces is manufactured for use on surfaces and equipment in dozens of settings including food processing plants, farms, food storage areas, restaurants, fast food operations, cafeterias, supermarkets, break rooms, schools, hospitals and other institutions, as well as in homes. IV-7 for Food Contact Surfaces helps prevent cross-contamination in food contact environments and eliminates odors. IV-7 for Food Contact Surfaces provides an advantageous combination of efficiency, high efficacy and low toxicity by rapidly eliminating dangerous pathogens, yet it does not create irritating fumes and does not require rinsing.
IV-7 Water Treatment™ is a liquid concentrate containing SDC effective against a broad spectrum of bacteria, virus and fungus in a stable, non-toxic, tasteless, odorless and colorless solution. IV-7 water treatment is so powerful that just seven drops treat an entire gallon (approximately four liters) of water. Earlier this year, PURE shipped IV-7 Water Treatment to Haiti for use in earthquake-ravaged areas. Project Hope distributed the product, which was sufficient to purify 40 million gallons of water for safe drinking. The water treatment does not carry United States registration and is not available for sale in the US.
Additional information about IV-7 products isavailable at www.IV-7.net.
About Richmont
Richmont is an experienced team of sales and marketing experts. It is headed by John Rochon, who has spent 35 years successfully building and promoting a host of well-known consumer and business-to-business brands. Richmont Sciences is owned by privately held Richmont Holdings (www.richmontholdings.com). Richmont Sciences functions as the sales and marketing arm for PURE’s disinfectant, santizer and water treatment products in domestic and international markets.
About PURE Bioscience
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project,” "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
SAN DIEGO (October 28, 2010) – PURE Bioscience (NASDAQ: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that its marketing partner, Richmont Sciences (Richmont), has established distribution of PURE’s SDC-based IV-7™ products in the Middle East region. Under this arrangement, PURE sells IV-7 products to Richmont for resale into the Middle East, where the IV-7 water treatment and disinfection products have been registered by the United Arab Emirates-Dubai Municipality. Richmont is initially focusing on distribution of IV-7 Water Treatment™.
Michael L. Krall, President and CEO of PURE Bioscience, stated, “Much of the Middle East’s drinking water is produced from desalination plants, and protecting stored drinking water from contamination and microbial growth presents a challenge to government, industry and consumers. We look forward to working with Richmont to provide a range of SDC-based products throughout the region.”
“The water purification and disinfecting technology of IV-7 products is a major scientific advance,” said John Rochon, Chairman of Richmont. “Safe water is a precious gift. Every day, far too many people become sick or even die from drinking or being exposed to contaminated water. This disaster can and must be prevented. We are determined to bring this new, lifesaving water treatment technology to families throughout the world.”
Richmont said that it has reached an agreement with Dubai-based High Scope General Trading LLC (High Scope) for the sale of IV-7 products in the Middle East region. “We are very pleased to join with High Scope in this effort and they will be an outstanding partner with us to bring IV-7 products to government, businesses and consumers,” said Mr. Rochon.
IV-7 Water Treatment contains PURE’s SDC technology, based on a proprietary molecule of ionic silver stabilized in citric acid. When used as directed for drinking water, the product provides safe, tasteless and odorless protection and can substantially reduce the incidence of gastrointestinal illness caused by contaminated water. As few as two ounces of IV-7 Water Treatment can treat 200 gallons of water in just minutes with no harm to the environment and no toxic side effects.
About IV-7 Products
IV-7 Ultimate Germ Defense™ can be used to kill germs on hard surfaces in a wide variety of settings, such as homes, offices, schools, hospitals, medical and dental clinics, restaurants, hotels, animal shelters, public facilities and many more. Unlike traditional alcohol- or bleach-based surface disinfectants, IV-7 Ultimate Germ Defense requires no hazard or warning statements and carries bacterial kill times as quick as 30 seconds, compared with up to 10 minutes for competing products. IV-7 Ultimate Germ Defense provides powerful protection – even against resistant pathogens such as MRSA – and continues to kill bacteria for up to 24 hours after usage; yet, with its EPA Category IV rating, the least-toxic classification, IV-7 Ultimate Germ Defense is also ideal for use in sensitive children’s areas.
IV-7 Ultimate Germ Defense for Food Contact Surfaces™ harnesses the same broad-spectrum disinfecting power as Ultimate Germ Defense combined with registration by the US EPA for food contact surface sanitization while maintaining the EPA Category IV rating. IV-7 Ultimate Germ Defense for Food Contact Surfaces is manufactured for use on surfaces and equipment in dozens of settings including food processing plants, farms, food storage areas, restaurants, fast food operations, cafeterias, supermarkets, break rooms, schools, hospitals and other institutions, as well as in homes. IV-7 for Food Contact Surfaces helps prevent cross-contamination in food contact environments and eliminates odors. IV-7 for Food Contact Surfaces provides an advantageous combination of efficiency, high efficacy and low toxicity by rapidly eliminating dangerous pathogens, yet it does not create irritating fumes and does not require rinsing.
IV-7 Water Treatment™ is a liquid concentrate containing SDC effective against a broad spectrum of bacteria, virus and fungus in a stable, non-toxic, tasteless, odorless and colorless solution. IV-7 water treatment is so powerful that just seven drops treat an entire gallon (approximately four liters) of water. Earlier this year, PURE shipped IV-7 Water Treatment to Haiti for use in earthquake-ravaged areas. Project Hope distributed the product, which was sufficient to purify 40 million gallons of water for safe drinking. The water treatment does not carry United States registration and is not available for sale in the US.
Additional information about IV-7 products isavailable at www.IV-7.net.
About Richmont
Richmont is an experienced team of sales and marketing experts. It is headed by John Rochon, who has spent 35 years successfully building and promoting a host of well-known consumer and business-to-business brands. Richmont Sciences is owned by privately held Richmont Holdings (www.richmontholdings.com). Richmont Sciences functions as the sales and marketing arm for PURE’s disinfectant, santizer and water treatment products in domestic and international markets.
About PURE Bioscience
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project,” "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Monday, October 25, 2010
Sunday, October 24, 2010
Saturday, October 23, 2010
Saturday, October 16, 2010
Thursday, October 14, 2010
Wednesday, October 13, 2010
Right Product-Right Time-Right Marketing Channel
RIGHT PRODUCT – RIGHT TIME – RIGHT MARKETING CHANNEL
The following article appeared in the New York Times on August 2nd. This only continues to verify that IV-7 Direct is the best business opportunity in the world. We will have this article up on our websites shortly.
I encourage you to email this out to everyone you know. This is what IV-7 is all about. Articles like this are popping up all over the media and, to think, we have the only answer to this enormous and growing problem.
Let’s get out there and tell everyone. We have an obligation to inform people. This is all about grassroots marketing. It’s not about large commercial sales. It’s about Germ Defense Forums and telling your friends and neighbors. You’ve always wanted to be first in the beginning of a major opportunity. This is it. This is it!
http://www.nytimes.com/2010/08/03/health/03brod.html?_r=1&scp=1&sq=skin%20infections&st=cse
Count up how many people you tell today about IV-7 Direct. Keep a tally each and every day. Monitor your progress and watch your business grow, grow, grow!
Remember to have an eventful day today. And, most of all remember to say, “It’s not about me, It’s about YOU"
The following article appeared in the New York Times on August 2nd. This only continues to verify that IV-7 Direct is the best business opportunity in the world. We will have this article up on our websites shortly.
I encourage you to email this out to everyone you know. This is what IV-7 is all about. Articles like this are popping up all over the media and, to think, we have the only answer to this enormous and growing problem.
Let’s get out there and tell everyone. We have an obligation to inform people. This is all about grassroots marketing. It’s not about large commercial sales. It’s about Germ Defense Forums and telling your friends and neighbors. You’ve always wanted to be first in the beginning of a major opportunity. This is it. This is it!
http://www.nytimes.com/2010/08/03/health/03brod.html?_r=1&scp=1&sq=skin%20infections&st=cse
Count up how many people you tell today about IV-7 Direct. Keep a tally each and every day. Monitor your progress and watch your business grow, grow, grow!
Remember to have an eventful day today. And, most of all remember to say, “It’s not about me, It’s about YOU"
Dramatic Surge Seen in Kids Hospitalized with MRSA
Dramatic surge seen in kids hospitalized with MRSA
By LINDSEY TANNER (AP) – 1 day ago
CHICAGO — The number of children hospitalized with dangerous drug-resistant staph infections surged 10-fold in recent years, a study found.
Disease incidence increased from 2 cases to 21 cases per 1,000 hospital admissions from 1999 to 2008. Most infections were caught in the community, not in the hospital.
The study involved methicillin-resistant staph infections, called MRSA. These used to occur mostly in hospitals and nursing homes but they are increasingly showing up in other settings in children and adults. Recent evidence suggests hospital-acquired MRSA cases may be declining while community-acquired cases are becoming more common.
The results are "a good example of how something that is not unexpected remains alarming," said Dr. Buddy Creech, an infectious disease specialist at Vanderbilt University. He was not involved in the study.
The study involved 25 children's hospitals; the 10-fold increase in hospitalizations likely occurred nationwide, said Dr. Jason Newland, the lead author and an infectious disease physician at Children's Mercy Hospitals and Clinics and the University of Missouri-Kansas City.
Almost 30,000 children were hospitalized with MRSA infections at the hospitals studied during the 10-year period. Most had skin or muscle infections, and 374 youngsters with MRSA died. While Newland said it isn't clear if MRSA caused those deaths, it can be deadly and is blamed for more than 18,000 deaths in children and adults nationwide each year.
The study didn't examine whether deaths or the severity of infections increased.
The results were published Monday in the journal Pediatrics.
MRSA often begins as a pimple or boil on the skin. It can also spread to other parts of the body, including the bones or lungs, where it can cause pneumonia.
The study also found a coinciding increase in use of clindamycin, an antibiotic that comes in easy-to-use pills and liquid, and smaller increases for two other antibiotics. Another drug effective against MRSA, vancomycin, is only available intravenously and its use decreased during the study.
Newland said the increasing use of clindamycin is concerning because in some regions MRSA is already becoming resistant to the drug. Doctors need to use the antibiotic judiciously, he said.
Dr. Kenneth Alexander, the University of Chicago's pediatric infectious disease chief, said he agrees.
"Staph are incredibly cagey, and will ultimately find their way around any antibiotic in use," he said.
Research is needed to find other drugs that will work against MRSA, he said.
By LINDSEY TANNER (AP) – 1 day ago
CHICAGO — The number of children hospitalized with dangerous drug-resistant staph infections surged 10-fold in recent years, a study found.
Disease incidence increased from 2 cases to 21 cases per 1,000 hospital admissions from 1999 to 2008. Most infections were caught in the community, not in the hospital.
The study involved methicillin-resistant staph infections, called MRSA. These used to occur mostly in hospitals and nursing homes but they are increasingly showing up in other settings in children and adults. Recent evidence suggests hospital-acquired MRSA cases may be declining while community-acquired cases are becoming more common.
The results are "a good example of how something that is not unexpected remains alarming," said Dr. Buddy Creech, an infectious disease specialist at Vanderbilt University. He was not involved in the study.
The study involved 25 children's hospitals; the 10-fold increase in hospitalizations likely occurred nationwide, said Dr. Jason Newland, the lead author and an infectious disease physician at Children's Mercy Hospitals and Clinics and the University of Missouri-Kansas City.
Almost 30,000 children were hospitalized with MRSA infections at the hospitals studied during the 10-year period. Most had skin or muscle infections, and 374 youngsters with MRSA died. While Newland said it isn't clear if MRSA caused those deaths, it can be deadly and is blamed for more than 18,000 deaths in children and adults nationwide each year.
The study didn't examine whether deaths or the severity of infections increased.
The results were published Monday in the journal Pediatrics.
MRSA often begins as a pimple or boil on the skin. It can also spread to other parts of the body, including the bones or lungs, where it can cause pneumonia.
The study also found a coinciding increase in use of clindamycin, an antibiotic that comes in easy-to-use pills and liquid, and smaller increases for two other antibiotics. Another drug effective against MRSA, vancomycin, is only available intravenously and its use decreased during the study.
Newland said the increasing use of clindamycin is concerning because in some regions MRSA is already becoming resistant to the drug. Doctors need to use the antibiotic judiciously, he said.
Dr. Kenneth Alexander, the University of Chicago's pediatric infectious disease chief, said he agrees.
"Staph are incredibly cagey, and will ultimately find their way around any antibiotic in use," he said.
Research is needed to find other drugs that will work against MRSA, he said.
Salmonella Outbreak Sickens People in 10 States
Salmonella Outbreak Sickens People in 10 States
One of our top leaders in IV-7 Direct forwarded this link today. If you or anyone you are speaking to asks why we are doing what we do, just give them this link. Read the story and learn about the infant who was affected. This is why IV-7 Direct was formed. In just 24 hours we have representation in nearly 40 states. Not bad for just the "first" 24 hours. Imagine what we can do in the next six months!
Remember: Living Safely - Saving Lives. That's our motto!
http://www.aolnews.com/nation/article/salmonella-outbreak-sickens-people-in-10-states/19487557?icid=main%7Chtmlws-sb-w%7Cdl1%7Clink4%7Chttp%3A%2F%2Fwww.aolnews.com%2Fnation%2Farticle%2Fsalmonella-outbreak-sickens-people-in-10-states%2F19487557
One of our top leaders in IV-7 Direct forwarded this link today. If you or anyone you are speaking to asks why we are doing what we do, just give them this link. Read the story and learn about the infant who was affected. This is why IV-7 Direct was formed. In just 24 hours we have representation in nearly 40 states. Not bad for just the "first" 24 hours. Imagine what we can do in the next six months!
Remember: Living Safely - Saving Lives. That's our motto!
http://www.aolnews.com/nation/article/salmonella-outbreak-sickens-people-in-10-states/19487557?icid=main%7Chtmlws-sb-w%7Cdl1%7Clink4%7Chttp%3A%2F%2Fwww.aolnews.com%2Fnation%2Farticle%2Fsalmonella-outbreak-sickens-people-in-10-states%2F19487557
Alarming Uptick of Superbugs in Hospitals
CBS News Story on September 30, 2010
Alarming Uptick of Deadly Superbugs in Hospitals
Here’s a link to the CBS News Website on a story that Katie Couric did just last night. This is so timely for IV-7 Direct. But these stories are popping up now every day and multiple times a day.
This just reinforces why IV-7 Direct will become the largest direct sales network marketing company of all time worldwide. It’s so exciting to know that we alone have IV-7. No other company in the world has any product that comes even close to the effectiveness of IV-7. Like I keep saying, “No Competitive Argument.” Check it out!
http://www.cbsnews.com/stories/2010/09/30/eveningnews/main6916322.shtml?tag=broadcast
Alarming Uptick of Deadly Superbugs in Hospitals
Here’s a link to the CBS News Website on a story that Katie Couric did just last night. This is so timely for IV-7 Direct. But these stories are popping up now every day and multiple times a day.
This just reinforces why IV-7 Direct will become the largest direct sales network marketing company of all time worldwide. It’s so exciting to know that we alone have IV-7. No other company in the world has any product that comes even close to the effectiveness of IV-7. Like I keep saying, “No Competitive Argument.” Check it out!
http://www.cbsnews.com/stories/2010/09/30/eveningnews/main6916322.shtml?tag=broadcast
Its Coming!
A tremendous amount of excitement has been building in regards to IV-7 Direct. Leaders from all over the US, Canada and Mexico have been in contact with us to learn more. You do not want to miss out on this opportunity to be part of history. Join the war against germs by filling out the form below. Do not wait.IV-7 Direct is the most innovative and creditable company to burst onto the direct sales network marketing stage ever. With patented, EPA-registered products and a management team far and away more experienced than anything the industry has ever seen before, IV-7 Direct is destined to become the Gold Standard in the direct sales networking industry. You'll learn about our revolutionary process that has the power to transform the way we defend ourselves and our loved ones against bacteria and viruses.
A tremendous amount of excitement has been building in regards to IV-7 Direct. Leaders from all over the US, Canada and Mexico have been in contact with us to learn more. You do not want to miss out on this opportunity to be part of history. Join the war against germs by filling out the form below. Do not wait.
IV-7 Direct is the most innovative and creditable company to burst onto the direct sales network marketing stage ever. With patented, EPA-registered products and a management team far and away more experienced than anything the industry has ever seen before, IV-7 Direct is destined to become the Gold Standard in the direct sales networking industry.
Monday, October 11, 2010
Sunday, October 10, 2010
Friday, October 8, 2010
Create an Avalanche of FREE Targeted Traffic to Your Website Using the Power of Twitter: http://ping.fm/K9CwG
Wednesday, October 6, 2010
Monday, October 4, 2010
How many people knowing all the nasty virus', germs out there like MRSA,VRE, Norovirus, Rhinovirus, H1N1, E.Coli and Salmonella could invest in a company that has the patent on the molecule that is saving lives would you invest in it?
http://bit.ly/csZfx2
http://bit.ly/csZfx2
Friday, October 1, 2010
Subscribe to:
Posts (Atom)